| Old Articles: <Older 6251-6260 Newer> |
|---|
 |
The Motley Fool
March 23, 2010
Brian Orelli |
Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?   |
The Motley Fool
March 22, 2010
Brian Orelli |
Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio. |
IndustryWeek
March 17, 2010 |
First Up - The Audacity of Hopelessness Do our political leaders have the resolve to steer us from an unsustainable path? |
The Motley Fool
March 17, 2010
Brian Orelli |
An Aspiring Blockbuster Novartis gets some bad clinical-trial news on its blood pressure medication. |
The Motley Fool
March 16, 2010
Brian Orelli |
How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind. |
The Motley Fool
March 16, 2010
Brian Orelli |
No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move |
Chemistry World
March 15, 2010
Matt Wilkinson |
An agile future Nick Roelofs, president of Agilent Technology's life sciences group, discusses how the company is planning to ride the waves of the economic recovery. |
The Motley Fool
March 15, 2010
Brian Orelli |
Clinical Outcomes? Who Needs 'Em. Abbott's TriCor looks good on lab tests, but that's about all. |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
March 15, 2010
Brian Orelli |
Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison. |
| <Older 6251-6260 Newer> Return to current articles. |
